|Dr. Troy Edward Wilson J.D., Ph.D.||Chairman, CEO, Pres & Principal Financial Officer||984.61k||N/A||1969|
|Ms. Kathleen Ford||Chief Operating Officer||689.32k||62.51k||1947|
|Dr. Marc Grasso M.D.||Advisor||651.68k||N/A||1974|
|Ms. Kirsten Flowers||Chief Commercial Officer||642.98k||N/A||1975|
|Dr. Stephen Dale M.D.||Chief Medical Officer||811.58k||N/A||1972|
|Mr. Thomas Doyle||Principal Accounting Officer & Sr. VP of Fin. and Accounting||N/A||N/A||1971|
|Mr. Pete De Spain||Sr. VP of Investor Relations & Corp. Communications||N/A||N/A||N/A|
|Ms. Teresa Brophy Bair Esq., J.D.||Chief Legal Officer & Corp. Sec.||N/A||N/A||1971|
|Mr. James E. Basta J.D., Esq.||Chief Compliance Officer & Corp. Sec.||N/A||N/A||1966|
|Dr. Roger Bakale Ph.D.||VP and Head of CMC, Clinical & Commercial Manufacturing||N/A||N/A||N/A|
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A protein-protein interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; and tipifarnib, an orally bioavailable inhibitor of farnesyl transferase that is in Phase II clinical trials for the treatment of solid tumors and hematologic indications. The company has a clinical collaboration with Novartis to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression or PIK3CA mutation and/or amplification. Kura Oncology, Inc. was founded in 2014 and is headquartered in San Diego, California.
Kura Oncology, Inc.’s ISS governance QualityScore as of 31 July 2022 is 8. The pillar scores are Audit: 6; Board: 8; Shareholder rights: 8; Compensation: 9.